This protective effect may be further mediated by the effect of SSRI exposure on AVP secretion, with more well-controlled depression revealing little amelioration of preeclampsia risk, while more poorly controlled (moderate or severe depression) saw significant benefits of SSRI use on vasopressin release. This evidence concerns the gene AVP and depressive symptom measurement.